ABL, Inc. (ABL), and BIOQUAL, Inc. (BIOQUAL) announced today that they have signed a definitive agreement for BIOQUAL to acquire in-vivo animal model services-related assets from ABL. The companies also will enter into a Strategic Teaming Agreement for joint marketing after the sale is completed.

ABL, which has provided services to the life sciences industry for 50 years, currently operates a USDA-registered 35,000 square-foot animal laboratory facility which is fully accredited by the American Association for the Accreditation of Laboratory Animal Care International (AAALAC). ABL performs vital animal model studies for government and commercial clients. BIOQUAL is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in-vivo and in-vitro studies including those requiring Good Laboratory Practice (GLP) documentation and conditions.

Subject to landlord approval, BIOQUAL will assume the lease for the animal laboratories, acquire related assets, assume certain contracts, and perform additional animal model services as a subcontractor to ABL. ABL will no longer provide in-vivo animal model services. BIOQUAL and ABL will jointly market BIOQUAL’s animal model services and ABL’s in-vitro laboratory services under a three-year Strategic Teaming Agreement. The transaction, which has been approved by BIOQUAL’s and ABL’s boards of directors, is also conditioned on approval by the National Institutes of Health and other customary approvals.

“Today's transaction will increase BIOQUAL’s presence in the animal model services business and provides an opportunity for ABL and BIOQUAL to work together to expand their businesses,” said Mark Lewis, President and CEO of BIOQUAL. “This acquisition will add a state-of-the-art animal laboratory facility and skilled staff to BIOQUAL’s existing capabilities to serve government and private markets.”

Thomas VanCott, President and CEO of ABL stated, “ABL is very excited to enter into this partnership with BIOQUAL. Working together will provide our clients with enhanced in-vivo capabilities that are fully integrated with our exceptional laboratory in-vitro services and program management functions. This arrangement gives ABL greater flexibility to expand our laboratory services both in the preclinical areas and in Good Clinical Laboratory Practices (GCLP) testing to support human clinical trials.”

ABL, Inc. is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, process and assay development, preclinical studies, in-vitro laboratory services, clinical immunomonitoring, and Phase I/II cGMP biologics manufacturing. Since 2001, ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.

BIOQUAL, Inc. (BIOQ (Pinksheets)), based in Rockville, Maryland, is committed to providing quality research, development, consulting, and testing/assay services to commercial clients and Government laboratories. For more information about BIOQUAL, please visit its website at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including the operative results of the subject transaction, risks relating to the ability to continue to extend current government contracts and obtain new contracts; the actual cost incurred in performing its contracts; uncertainties relating to pre-clinical trials; dependence on third parties; and future capital needs.

BIOQUAL, Inc.Mark G. Lewis, Ph.D., CEO301-251-2801orABL, Inc.Thomas VanCott, Ph.D., CEO800-225-5600

Bioqual (PK) (USOTC:BIOQ)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Bioqual (PK) Charts.
Bioqual (PK) (USOTC:BIOQ)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Bioqual (PK) Charts.